Drug Research
Roquette Reveals New US-Based Pharmaceutical Innovation Center
Roquette, a global leader in plant-based ingredients and a leading provider of naturally-derived pharmaceutical excipients, announces its plans to open a new Innovation Center in the US to further the advancement of prescription drugs – and beyond. Located in...
Drug Research
Operations commence at Genezen’s lenti- and retroviral vector process development lab
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has officially opened its new process development and analytical lab.
The lab will deliver a full...
Drug Research
Nykode Therapeutics Selects BioConnection to Manufacture Lead Vax Candidate
Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new...
Drug Research
Lonza and Bioqube Ventures Sign a Framework Agreement for the Future Development of Biologics and Small Molecules for Bioqubes Portfolio Companies
Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced a framework agreement covering a strategic collaboration...
Drug Research
Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001
Valneva SE, a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years....
Drug Research
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional...
Drug Research
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced it has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize an antibody,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















